AstraZeneca PLC Director/PDMR Shareholding
12 6월 2024 - 11:00PM
RNS Regulatory News
RNS Number : 1735S
AstraZeneca PLC
12 June 2024
12 June 2024
Transaction by Person
Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that,
on 10 June 2024, it was notified by Pascal
Soriot, Chief Executive Officer, that, on 10 June
2024, Mr Soriot ceased to be
beneficially interested in 297,418 Ordinary Shares of $0.25 each in the Company, following the
gift of those shares to family members for nil
consideration.
Further details are set out in the attached
notification, made in accordance with the requirements of the EU
Market Abuse Regulation (as it forms part of UK law pursuant to the
European Union (Withdrawal) Act 2018).
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Pascal Soriot
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.25 each in
AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Gift of shares to family members for
nil consideration
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
0
|
297,418
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single
transaction
|
|
e)
|
Date of the transaction
|
10 June 2024
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca.
Contacts
For details on how to contact the
Investor Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHUUSRRSAUNAAR
Astrazeneca (LSE:AZN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Astrazeneca (LSE:AZN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
